Plain-English translation of NCT07400289 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new FibroScan device — a special ultrasound scanner that measures scarring in the liver. Instead of using multiple different probes (scanning tools), this new device uses just one probe to do the same job. The study wants to see if the single-probe scanner gives the same reliable results as the standard multi-probe scanners that doctors currently use.
Currently, doctors need to switch between different probe sizes to scan different patients' livers properly. A single-probe scanner could make the examination simpler, faster, and more convenient for both patients and medical staff.
You likely qualify if…
You likely don't qualify if…
You would visit a hepatology clinic at one of the study sites (in Hong Kong or France) for liver imaging scans. During your visit, you would receive FibroScan examinations using both the new single-probe device and the standard multi-probe scanners so the researchers can compare how well they work. The scans are non-invasive and painless, similar to an ultrasound.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
France
Hong Kong
Sponsor
Echosens
Collaborators
Novotech CRO
Enrollment target
~389 participants
Started
November 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anne Llorca
Echosens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.